NCT00487058View on ClinicalTrials.gov

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2008

Conditions
Advanced Solid Tumors
Interventions
DRUG

Gimatecan

Trial Locations (1)

Unknown

Saitama Prefecture

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY